Cargando…
Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma
BACKGROUND: The prognostic values of interim and post-therapy fluorine-18-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) scanning have been confirmed in several subtypes of lymphoma. However, its prognostic value in Burkitt’s lymphoma has not been...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668634/ https://www.ncbi.nlm.nih.gov/pubmed/26630874 http://dx.doi.org/10.1186/s40880-015-0057-z |
_version_ | 1782404000356761600 |
---|---|
author | Wei, Wen-Xiao Huang, Jia-Jia Li, Wen-Yu Zhang, Xu Xia, Yi Jiang, Wen-Qi Fan, Wei Li, Zhi-Ming |
author_facet | Wei, Wen-Xiao Huang, Jia-Jia Li, Wen-Yu Zhang, Xu Xia, Yi Jiang, Wen-Qi Fan, Wei Li, Zhi-Ming |
author_sort | Wei, Wen-Xiao |
collection | PubMed |
description | BACKGROUND: The prognostic values of interim and post-therapy fluorine-18-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) scanning have been confirmed in several subtypes of lymphoma. However, its prognostic value in Burkitt’s lymphoma has not been clearly defined. The aim of the present study was to assess the prognostic value of PET/CT scanning during different treatment processes of Burkitt’s lymphoma. METHODS: A total of 29 adult patients with newly diagnosed Burkitt’s lymphoma were retrospectively involved in this study; of them, 23 patients underwent baseline PET/CT, 15 patients underwent mid-therapy PET/CT after 1–4 cycles of chemotherapy, and 17 patients underwent post-therapy PET/CT after all planned first-line chemotherapy cycles. Mid-therapy and post-therapy PET/CT results (positive vs. negative) were visually interpreted according to the criteria of the International Harmonization Project. The reduction in the maximum standardizes uptake values (∆SUVmax) of 25%, 50%, and 75% were regarded as cutoff points. Overall survival (OS) and progression-free survival (PFS) were regarded as the major endpoints. RESULTS: The median OS and PFS were 27.6 months (range 6.5–78.3 months) and 27.2 months (range 3.0–78.3 months), respectively. The median SUVmax of the baseline PET/CT was 18.3 (range 1.6–35.9), whereas the median SUVmax of the mid-therapy and post-therapy PET/CT decreased to 4.0 (range 0–17.6) and 3.0 (range 0–14.5), respectively. The patients’ Eastern Cooperative Oncology Group (ECOG) scores (<2 vs. ≥2) were significantly associated with the baseline PET/CT SUVmax. The mid-therapy and post-therapy PET/CT results (positive vs. negative) showed no significant association with OS or PFS. The optimal cutoff ∆SUVmax from the baseline to the post-therapy PET/CT that could predict a change in OS in patients with Burkitt’s lymphoma was 50% (P = 0.019). CONCLUSIONS: (18)F-FDG uptake was intense in Burkitt’s lymphoma, and there was a significant reduction in SUVmax during the interim and post-therapy PET/CT procedures. A ∆SUVmax of greater than 50% was a favorable cutoff point to predict the OS of Burkitt’s lymphoma patients. |
format | Online Article Text |
id | pubmed-4668634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46686342015-12-09 Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma Wei, Wen-Xiao Huang, Jia-Jia Li, Wen-Yu Zhang, Xu Xia, Yi Jiang, Wen-Qi Fan, Wei Li, Zhi-Ming Chin J Cancer Original Article BACKGROUND: The prognostic values of interim and post-therapy fluorine-18-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) scanning have been confirmed in several subtypes of lymphoma. However, its prognostic value in Burkitt’s lymphoma has not been clearly defined. The aim of the present study was to assess the prognostic value of PET/CT scanning during different treatment processes of Burkitt’s lymphoma. METHODS: A total of 29 adult patients with newly diagnosed Burkitt’s lymphoma were retrospectively involved in this study; of them, 23 patients underwent baseline PET/CT, 15 patients underwent mid-therapy PET/CT after 1–4 cycles of chemotherapy, and 17 patients underwent post-therapy PET/CT after all planned first-line chemotherapy cycles. Mid-therapy and post-therapy PET/CT results (positive vs. negative) were visually interpreted according to the criteria of the International Harmonization Project. The reduction in the maximum standardizes uptake values (∆SUVmax) of 25%, 50%, and 75% were regarded as cutoff points. Overall survival (OS) and progression-free survival (PFS) were regarded as the major endpoints. RESULTS: The median OS and PFS were 27.6 months (range 6.5–78.3 months) and 27.2 months (range 3.0–78.3 months), respectively. The median SUVmax of the baseline PET/CT was 18.3 (range 1.6–35.9), whereas the median SUVmax of the mid-therapy and post-therapy PET/CT decreased to 4.0 (range 0–17.6) and 3.0 (range 0–14.5), respectively. The patients’ Eastern Cooperative Oncology Group (ECOG) scores (<2 vs. ≥2) were significantly associated with the baseline PET/CT SUVmax. The mid-therapy and post-therapy PET/CT results (positive vs. negative) showed no significant association with OS or PFS. The optimal cutoff ∆SUVmax from the baseline to the post-therapy PET/CT that could predict a change in OS in patients with Burkitt’s lymphoma was 50% (P = 0.019). CONCLUSIONS: (18)F-FDG uptake was intense in Burkitt’s lymphoma, and there was a significant reduction in SUVmax during the interim and post-therapy PET/CT procedures. A ∆SUVmax of greater than 50% was a favorable cutoff point to predict the OS of Burkitt’s lymphoma patients. BioMed Central 2015-12-02 /pmc/articles/PMC4668634/ /pubmed/26630874 http://dx.doi.org/10.1186/s40880-015-0057-z Text en © Wei et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Article Wei, Wen-Xiao Huang, Jia-Jia Li, Wen-Yu Zhang, Xu Xia, Yi Jiang, Wen-Qi Fan, Wei Li, Zhi-Ming Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma |
title | Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma |
title_full | Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma |
title_fullStr | Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma |
title_full_unstemmed | Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma |
title_short | Prognostic values of interim and post-therapy (18)F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma |
title_sort | prognostic values of interim and post-therapy (18)f-fdg pet/ct scanning in adult patients with burkitt’s lymphoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668634/ https://www.ncbi.nlm.nih.gov/pubmed/26630874 http://dx.doi.org/10.1186/s40880-015-0057-z |
work_keys_str_mv | AT weiwenxiao prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma AT huangjiajia prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma AT liwenyu prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma AT zhangxu prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma AT xiayi prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma AT jiangwenqi prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma AT fanwei prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma AT lizhiming prognosticvaluesofinterimandposttherapy18ffdgpetctscanninginadultpatientswithburkittslymphoma |